CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Stock analysts at Zacks Research reduced their Q2 2025 earnings estimates for CRISPR Therapeutics in a research note issued on Monday, December 9th. Zacks Research analyst R. Department now forecasts that the company will earn ($1.48) per share for the quarter, down from their previous estimate of ($1.47). The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.17) per share. Zacks Research also issued estimates for CRISPR Therapeutics' Q3 2025 earnings at ($1.39) EPS, Q4 2025 earnings at ($1.32) EPS, FY2025 earnings at ($5.70) EPS, Q1 2026 earnings at ($1.40) EPS, Q2 2026 earnings at ($1.11) EPS, Q3 2026 earnings at ($0.60) EPS and FY2026 earnings at ($3.44) EPS.
CRSP has been the subject of a number of other research reports. Barclays dropped their price objective on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an "equal weight" rating for the company in a report on Wednesday, November 6th. StockNews.com upgraded shares of CRISPR Therapeutics to a "sell" rating in a report on Wednesday. Royal Bank of Canada restated a "sector perform" rating and issued a $53.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Needham & Company LLC reaffirmed a "buy" rating and set a $84.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Finally, Chardan Capital restated a "buy" rating and set a $94.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $77.93.
Get Our Latest Stock Analysis on CRSP
CRSP stock opened at $47.78 on Thursday. The stock has a market capitalization of $4.08 billion, a P/E ratio of -16.88 and a beta of 1.62. The firm has a 50-day moving average price of $48.82 and a 200-day moving average price of $51.33. CRISPR Therapeutics has a 12 month low of $43.42 and a 12 month high of $91.10.
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.42) by $0.41. The business had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same quarter in the prior year, the business posted ($1.41) earnings per share.
In other news, CEO Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $198,680.04. Following the completion of the transaction, the chief executive officer now directly owns 226,540 shares in the company, valued at approximately $10,484,271.20. The trade was a 1.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the completion of the sale, the general counsel now owns 62,597 shares in the company, valued at $2,896,989.16. This represents a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 50,382 shares of company stock worth $2,744,179. 4.10% of the stock is owned by corporate insiders.
A number of large investors have recently modified their holdings of CRSP. SFE Investment Counsel grew its position in CRISPR Therapeutics by 3.6% during the second quarter. SFE Investment Counsel now owns 5,846 shares of the company's stock valued at $316,000 after acquiring an additional 203 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in CRISPR Therapeutics by 4.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 4,606 shares of the company's stock valued at $249,000 after acquiring an additional 211 shares during the period. Boston Family Office LLC increased its stake in CRISPR Therapeutics by 2.2% in the 3rd quarter. Boston Family Office LLC now owns 9,763 shares of the company's stock worth $459,000 after purchasing an additional 213 shares during the period. Bedell Frazier Investment Counselling LLC boosted its position in CRISPR Therapeutics by 0.8% during the 3rd quarter. Bedell Frazier Investment Counselling LLC now owns 26,357 shares of the company's stock valued at $1,238,000 after buying an additional 218 shares during the period. Finally, National Bank of Canada FI grew its holdings in CRISPR Therapeutics by 35.0% in the 2nd quarter. National Bank of Canada FI now owns 848 shares of the company's stock worth $46,000 after acquiring an additional 220 shares during the last quarter. Institutional investors own 69.20% of the company's stock.
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider CRISPR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.
While CRISPR Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.